Specifically, immunoblots showed that the expression rates of both (Figure 2A) carbamoyl phosphate synthetase (CPS1) and (Figure 2B) ornithine transcarbamylase (OTC)—both normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH)—were significantly elevated in hepatocytes from NASH patients when compared with those obtained from NAFL patients. This evidence concerns the gene GAPDH and metabolic dysfunction-associated steatohepatitis.